There are currently 53 active clinical trials seeking participants for Glioblastoma Multiforme research studies. The states with the highest number of trials for Glioblastoma Multiforme participants are California, Texas, New York and Ohio.
hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)
NCT05052957
Recruiting
This phase II trial studies the effect of P140K MGMT hematopoietic stem cells, O6-benzylguanine, temozolomide, and carmustine in treating participants with supratentorial glioblastoma or gliosarcoma who have recently had surgery to remove most or all of the brain tumor (resected). Chemotherapy drugs, such as 6-benzylguanine, temozolomide, and carmustine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing. Placing P140K MGMT, a ge... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
02/27/2024
Locations: University Hospitals Cleveland Medical Center, Cleveland, Ohio
Conditions: Glioblastoma Multiforme, Glioblastoma Multiforme, Adult, Supratentorial Glioblastoma, Supratentorial Gliosarcoma
Register for Updates
A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.
NCT05977322
Recruiting
The purpose of the study is to test the safety and dosing of [177Lu]Lu-FF58, a radioligand therapy for patients with advanced or metastatic tumors that express proteins known as integrins: alpha-v beta-3 integrin (αvβ3) and alpha-v beta-5 integrin (αvβ5). The study will also further characterize the radioligand imaging agent [68Ga]Ga-FF58 including its ability to identify tumor lesions and its safety profile.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Massachusetts General Hospital Massachusetts General Hospital, Boston, Massachusetts +6 locations
Conditions: Pancreatic Ductal Adenocarcinoma, Gastroesophageal Adenocarcinoma, Glioblastoma Multiforme
Register for Updates
Neurosurgical Neuronavigation Using Resting State MRI and Machine Learning
NCT05864976
Recruiting
This study is investigating the use of a computer algorithm to analyze scans of the brain before surgery to predict how a person's tumor will respond to treatment.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Glioblastoma Multiforme
Register for Updates
A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment
NCT05708352
Recruiting
This is a Phase 2, randomized two-armed, multi-site study of 170 patients with newly diagnosed glioblastoma multiforme. Patients will be randomized 1:1 to receive Keto Diet, or Standard Anti-Cancer Diet. All patients will receive standard of care treatment for their glioblastoma. The Keto Diet intervention will be for an 18-week period and conducted by trained research dietitians. Daily ketone and glucose levels will be recorded to monitor Keto Diet adherence. This two-armed randomized multi-si... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/14/2024
Locations: Cedars-Sinai Medical Center, Los Angeles, California +4 locations
Conditions: Glioblastoma Multiforme
Register for Updates
Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.
NCT04712721
Recruiting
This is a First-In-Human (FIH) study of [68Ga]-FF58 to characterize the imaging properties, safety, biodistribution and dosimetry properties of [68Ga]-FF58 in adults with relapsed or refractory (r/r) glioblastoma multiforme (GBM), breast cancer (BC) that has metastasized to the brain, gastroesophageal adenocarcinoma (GEA) or pancreatic ductal adenocarcinoma (PDAC) expected to overexpress alpha-v beta 3 (αvβ3) and alpha-v beta 5 (αvβ5) integrins.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/05/2024
Locations: City of Hope National Medical Center Dept.ofCityofHopeMedicalCtr1, Duarte, California +3 locations
Conditions: Glioblastoma Multiforme, Brain Neoplasms, Gastroesophageal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
Register for Updates
Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme
NCT02177578
Recruiting
In this study patients will be treated with 6 weeks of radiation therapy plus temozolomide chemotherapy according to the standard of care. However, the radiation treatment plan will be modified to deliver an higher than routine radiation dose to the subventricular zone which is an area of the brain that contains stem cells that some scientists believe may contribute to glioblastoma recurrence. The purpose of the study is to see if the tumor is controlled for a longer period of time in patients t... Read More
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
06/05/2024
Locations: Sibley Memorial Hospital, Washington, District of Columbia +2 locations
Conditions: Glioblastoma Multiforme
Register for Updates
Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM)
NCT05120284
Recruiting
Conduct a multicenter, open label Phase IIA trial of oral DCA in 40 surgical patients with recurrent GBM who have clinically indicated debulking surgery planned. No patients will be recruited at UF. Patients will be genotyped to establish safe dosing regimens and will be randomized to receive DCA (N=20) or no DCA (N=20) for one week prior to surgery. Deidentified blood and tumor tissue obtained at surgery will be assessed at UF for biochemical markers of DCA dynamics.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
06/05/2024
Locations: Sibley Memorial Hospital, Washington, District of Columbia +2 locations
Conditions: Glioblastoma Multiforme
Register for Updates
Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme
NCT00083512
Recruiting
This study will collect blood and urine samples from patients undergoing radiation therapy for glioblastoma multiforme (a type of brain tumor) to investigate the effects of this treatment on blood cells and certain proteins. The information from this study may help scientists develop new tests to measure radiation exposure and find new ways to treat cancer with radiation, and help determine which kinds of patients or tumors respond better to radiation therapy. Two proteins of particular interest... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/04/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Glioblastoma Multiforme
Register for Updates
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
NCT05303467
Recruiting
The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/24/2024
Locations: University of California San Francisco, San Francisco, California +4 locations
Conditions: Glioblastoma Multiforme, Recurrent Glioblastoma
Register for Updates
A Phase 2 Study of NanO2(TM) Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM
NCT03862430
Recruiting
This clinical trial is testing the safety and efficacy of NanO2TM administered via intravenous infusion in combination with standard radiation and chemotherapy. NanO2TM is being developed to increase the amount of oxygen delivered to tumors which is hoped to increase the effectiveness of radiation therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/14/2024
Locations: Center for Neurosciences, Tucson, Arizona +8 locations
Conditions: Glioblastoma Multiforme
Register for Updates
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
NCT03175224
Recruiting
To assess: efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET efficacy of APL-101 as an add-on therapy to EGFR inhibitor for the treatment of NSCLC harboring EGFR activating mutations and developed acquired resistanc... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/08/2024
Locations: Loma Linda University Medical Center, Loma Linda, California +90 locations
Conditions: Advanced Cancer, Renal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, NSCLC, Lung Cancer, Brain Tumor, Glioblastoma Multiforme, Solid Tumors, EGFR Gene Mutation, MET Amplification, HGF, Thyroid Cancer, Pancreatic Cancer, Colon Cancer, MET Alteration, MET Fusion, Exon 14 Skipping
Register for Updates
Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial
NCT04825275
Recruiting
This research is being done to find out if the study drug (posaconazole) can enter brain tumors at a high enough amount to stop the tumor cells from dividing. Posaconazole is a drug which doctors already use for fungal infections and is thought to be able to effect tumor cells. As treatments for this type of brain tumor are limited, it is hoped that the results of this study will help to determine if the study drug should be studied further as a possible treatment.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/08/2024
Locations: Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania
Conditions: Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain, Glioblastoma Multiforme, Adult
Register for Updates